 So we have these new types of tests called minimal residual disease to say, you know what? Your scans look okay, but there is still a small number of cells circulating in the blood. Let's do another round of chemo to make sure we get them all. So it's monitoring the response to see, was it effective? This has been the AZ Tech Roundtable. I'm Matt Battaglia. I want to thank everybody again for tuning in. We will catch you next time.